興科蓉醫藥(06833.HK)獲奧克特琺瑪人血白蛋白中國內地獨家經銷權
格隆匯2月16日丨興科蓉醫藥(06833.HK)發佈公吿,集團的現有業務夥伴Octapharma AG已確認四川興科蓉藥業有限責任公司(即公司的全資附屬公司)為奧克特琺瑪於法國Lingolsheim製造工廠生產的10克奧克特琺瑪人血白蛋白(20%,50毫升)的中國內地獨家經銷商,期限自2022年2月1日至2023年12月31日,其為集團與Octapharma AG之間業務合作的新增授權。
集團的主要業務是於中國內地從事改善人體血漿藥品、抗生素及專注於治療領域與人體血漿製品及其他快速增長類別互補的其他藥品的市場營銷、推廣及渠道管理服務。董事相信,通過擴大集團銷售及╱或分銷的藥品,將多元化集團的產品基礎,這有利於集團業務,並將為集團財務業績作出正面貢獻及可能提升股東價值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.